The formal purchasing channels for ensifentrine-Ohtuvayre and suggestions on preventing the risks of counterfeit drugs

Ensifentrine (trade name Ohtuvayre) is a new dual phosphodiesterase inhibitor used to treat respiratory diseases such as chronic obstructive pulmonary disease (COPD). The drug is not currently on the market in China, nor is it included in the medical insurance system. Therefore, domestic patients cannot purchase it directly through hospitals or regular pharmacies and need to obtain it through overseas formal channels.

Currently, Ohtuvayre is only approved for sale in the United States and can be purchased legally through overseas pharmacies or international medical services. For example, the US version of Ohtuvayre can be purchased through some authorized pharmacies in Hong Kong. Each box is 3mg/2.5mL (60 doses), and the price is about 44,500 Hong Kong dollars. When purchasing, patients should confirm whether the pharmacy has legal authorization and drug registration information to ensure that the drugs purchased are original and genuine.

Because medicines are expensive and cannot be purchased directly in the country, patients may be at risk of counterfeit medicines. It is recommended to purchase through officially certified overseas pharmacies or international medical platforms recommended by doctors, and avoid purchasing through informal channels, personal channels or social platforms. At the same time, after receiving the medicine, you should carefully check the packaging, batch number and expiration date of the medicine. If necessary, verify the authenticity through official channels.

Before purchasing and usingOhtuvayre, patients should consult a professional doctor to understand the dosage, course of treatment and possible adverse reactions, and follow up regularly during use to evaluate efficacy and safety. Strictly following doctor's guidance and purchasing through formal channels not only ensures drug efficacy, but also minimizes economic and health risks.

Reference materials:https://www.drugs.com/